Lithuania Allocates €13 Million for Reimbursed Medicines by Year-End

Changes taking effect in November include faster access to ophthalmology consultations in urgent cases, while 12 innovative medicines for cancer, cardiovascular conditions and other diseases have been added to the reimbursed medicines list. Approximately €13 million has been allocated for medicine reimbursement by the end of 2026. The measures create opportunities for pharmaceutical suppliers, healthcare providers and medical-service planners. HPC can support healthcare market research, procurement analysis and medical-sector partnership development.